Oncos Therapeutics Announces Clinical Advisory Board
Oncos Therapeutics announces Clinical Advisory Board for its oncolytic virus and cancer immunotherapy development programs July 5th, 2012. Helsinki, Finland - Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB). Bringing together a group of recognized leading experts in Oncology and Oncolytic Virus drug development, combining a wealth of clinical, strategic, and scientific experience in cancer drug development, immunotherapy, and oncolytic viruses,